Chemical formula: C₁₉H₂₇NO Molecular mass: 285.431 g/mol PubChem compound: 441278
Pentazocine has both agonist and antagonist action at opioid receptors. Pentazocine interrupts nociceptive input in the spinal cord. These analgesic effects are probably due to agonist actions at ĸ-receptors. Pentazocine is a weak antagonist at µ-opioid receptors with about one fiftieth the potency of nalorphine.
Pentazocine is an opioid, benzomorphan derivative analgesic with actions and uses similar to those of morphine. It has weak narcotic antagonist actions.
Prolonged use of high doses of pentazocine may produce dependence. It is subject to abuse.
Pentazocine is absorbed from the gastro-intestinal tract.
Following administration by mouth, peak plasma concentrations are reached in 1 to 3 hours. After intramuscular injection, peak plasma concentrations are reached in 15 minutes to 1 hour. Pentazocine diffuses across the placenta.
Pentazocine is metabolised in the liver.
Only a small proportion of the dose administered appears unchanged in the urine.
There are no preclinical safety data of relevance to the prescriber which are additional to that already included in other sections of this summary.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
